A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3)

作者：C. Robert, Ardalan Davarifar, Yana G. Najjar, Caroline A. Nebhan, David C. Portnoy, O. Hamid, Dirk Schadendorf, Michael K. Wong, Nikhil I. Khushalani, Paolo A. Ascierto, Tawnya L. Bowles, M. Navarro, G. Gullo, Jason J. Luke · 发表于：EJC Skin Cancer · 年份：2025 · DOI：10.1016/j.ejcskn.2025.100638 · 研究领域：Cancer Immunotherapy and Biomarkers、Immunotherapy and Immune Responses、vaccines and immunoinformatics approaches